Pace Life Sciences Strengthens CDMO Capabilities with New Acquisition

• Pace Life Sciences, a CDMO, has acquired a laboratory facility in Lebanon, New Jersey from Curia.

• The acquisition expands Pace’s network to 9 sites, enhancing its capacity for FDA-registered central laboratory services.

• The move builds upon Pace’s leadership in the analytical services space to support emerging drug development partners.

Pace Life Sciences, a contract development and manufacturing organization (CDMO), has announced the acquisition of a laboratory facility in Lebanon, New Jersey. The facility, formerly known as Whitehouse Analytical Laboratories, was previously owned by Curia, a global CDMO company.

The site has a history of over a decade of cultivating partnerships across the biopharma industry, providing expertise and speed in development and commercial analytical laboratory services. “This acquisition builds upon our leadership in the analytical services space to support emerging drug development partners through commercialization activities,” said Eric Roman, CEO of Pace.

Philip Macnabb, CEO of Curia, praised the work done by the Lebanon site team, stating, “Over the years, our Lebanon site has offered specialized analytical services that are highly valued by customers.” However, he acknowledged that these services fell outside of Curia’s core capabilities, leading to the decision to pass the site to an owner with overlapping interests.

The acquisition expands the Pace Life Sciences network to 9 sites, supporting a wide spectrum of small and large molecule analytical services, formulation development, and early-stage drug product manufacturing services. The New Jersey location allows the company to expand its capacity for FDA-registered central laboratory services, including analytical chemistry, microbiology, container closure integrity testing (CCIT), sterility, and other packaging and delivery testing services.